3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Hepatitis C
1
Carcinoma, Hepatocellular
1
Interventions
tislelizumab
4
Sorafenib
3
Propranolol
3
ledipasvir
2
entecavir
2
donafenib
2
apatinib
2
Sofosbuvir
2
Ribavirin
2
Radiotherapy
2
Proton Therapy
2
Bevacizumab
2
sitravatinib
1
polysaccharide MGN3
1
palbociclib
1
lenvatinib
1
lens intermediate filament proteins
1
ledipasvir, sofosbuvir drug combination
1
envafolimab
1
elbasvir-grazoprevir drug combination
1
daclatasvir
1
camrelizumab
1
atezolizumab
1
anlotinib
1
Vitamin D
1
Urination
1
Tyrosine Kinase Inhibitors
1
Surgical Procedures, Operative
1
Simeprevir
1
Raltegravir Potassium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Carcinoma, Hepatocellular
×
elbasvir-grazoprevir drug combination
×
Clear all
NCT04546802
2020-09-14
HATCHeT
Bayside Health
Phase 3
Withdrawn